Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
Total Valuation
MiNK Therapeutics has a market cap or net worth of $55.86M. The enterprise value is $33.24M.
Market Cap$55.86M
Enterprise Value$33.24M
Share Statistics
MiNK Therapeutics has 4,694,155 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,694,155
Owned by Insiders4.32%
Owned by Institutions0.36%
Financial Efficiency
MiNK Therapeutics’s return on equity (ROE) is 0.55 and return on invested capital (ROIC) is 859.68%.
Return on Equity (ROE)0.55
Return on Assets (ROA)-1.89
Return on Invested Capital (ROIC)859.68%
Return on Capital Employed (ROCE)8.60
Revenue Per Employee0.00
Profits Per Employee-468.90K
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of MiNK Therapeutics is ―. MiNK Therapeutics’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio-1.33
Price to Fair Value-1.33
Price to FCF-2.73
Price to Operating Cash Flow-0.01
PEG Ratio0.04
Income Statement
In the last 12 months, MiNK Therapeutics had revenue of 0.00 and earned -10.78M in profits. Earnings per share was -2.90.
Revenue0.00
Gross Profit-215.44K
Operating Income-10.65M
Pretax Income-10.78M
Net Income-10.78M
EBITDA-10.57M
Earnings Per Share (EPS)-2.90
Cash Flow
In the last 12 months, operating cash flow was -1.35B and capital expenditures -2.00, giving a free cash flow of -1.35B billion.
Operating Cash Flow-1.35B
Free Cash Flow-1.35B
Free Cash Flow per Share-286.55
Dividends & Yields
MiNK Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.21
52-Week Price Change107.83%
50-Day Moving Average12.61
200-Day Moving Average11.97
Relative Strength Index (RSI)48.82
Average Volume (3m)39.56K
Important Dates
MiNK Therapeutics upcoming earnings date is Mar 24, 2026, Before Open (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date―
Financial Position
MiNK Therapeutics as a current ratio of 0.72, with Debt / Equity ratio of 0.00%
Current Ratio0.72
Quick Ratio0.72
Debt to Market Cap0.19
Net Debt to EBITDA-0.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, MiNK Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
MiNK Therapeutics EV to EBITDA ratio is -2.50, with an EV/FCF ratio of -2.77.
EV to Sales0.00
EV to EBITDA-2.50
EV to Free Cash Flow-2.77
EV to Operating Cash Flow-2.77
Balance Sheet
MiNK Therapeutics has $14.28M in cash and marketable securities with $5.73M in debt, giving a net cash position of $8.56M billion.
Cash & Marketable Securities$14.28M
Total Debt$5.73M
Net Cash$8.56M
Net Cash Per Share$1.82
Tangible Book Value Per Share-$5.23
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for MiNK Therapeutics is $35.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$35.00
Price Target Upside194.12% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast21.48%